Blueshift Asset Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Blueshift Asset Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,722	Closed	-$229K	–	1167
2021 Q4	$229K	Sell	2,722 -1,889	-41%	-$146K	0.02%	719
2021 Q3	$307K	Buy	+4,611	New	+$266K	0.02%	803
2021 Q2	–	Sell	-4,886	Closed	-$212K	–	1212
2021 Q1	$212K	Sell	4,886 -1,622	-25%	-$69.8K	0.02%	757
2020 Q4	$338K	Buy	+6,508	New	+$294K	0.04%	507

Other funds holding ZNTL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Blueshift Asset Management's ZNTL Position: Q1 2022 in Review

Blueshift Asset Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2022, closing a stake of 2,722 shares — an estimated $229K sold.

Blueshift Asset Management first reported a position in ZNTL in Q4 2020 and held it in 4 quarters. The position peaked at $338K in Q4 2020. 128 funds tracked by Wall St. Rank hold ZNTL as of Q1 2022.

Blueshift Asset Management reported no remaining Zentalis Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Blueshift Asset Management sold 2,722 Zentalis Pharmaceuticals shares in Q1 2022, an estimated $229K.
Blueshift Asset Management first reported a position in Zentalis Pharmaceuticals in Q4 2020 and held it in 4 quarters.
Blueshift Asset Management's Zentalis Pharmaceuticals position peaked at $338K in Q4 2020.
128 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2022.

Based on Blueshift Asset Management's 13F filing for Q1 2022, filed 12 May 2022.